Jazeta

Sitagliptin, the active ingredient in Jazeta, is a DPP‑4 inhibitor presented as an oral tablet for oral administration. It is indicated to improve glycemic control in adults with type 2 diabetes mellitus by enhancing the incretin effect, which increases glucose‑dependent insulin secretion and reduces post‑prandial glucagon release.

GNH USA supplies Jazeta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for this antidiabetic medication. Our network ensures timely delivery and compliance with local import requirements.

Sitagliptin is a DPP‑4 inhibitor used in the management of type 2 diabetes mellitus, either alone or as part of combination therapy. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to further improve glycemic control. - Type 2 diabetes mellitus (adjunct to diet and exercise): supports glycemic management when lifestyle measures are insufficient.

Sitagliptin may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Upper respiratory tract infection: symptoms such as sore throat or nasal congestion. - Diarrhoea: loose stools that are usually self‑limiting.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes. - Arthralgia: unexplained joint pain that may be persistent.

When prescribing or dispensing Jazeta, consider the following safety measures. - Renal function: assess baseline renal function and avoid use in patients with severe impairment. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Pancreatitis: monitor for persistent abdominal pain and elevated enzymes. - Heart failure: use with caution in patients with a history of congestive heart failure. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Sitagliptin can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Sulfonylureas or insulin: increased risk of hypoglycaemia. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sitagliptin plasma levels. - Co‑administration with another DPP‑4 inhibitor: no additive benefit and increased risk of side effects.

Moderate Interactions (Monitor Closely): - Diuretics: may affect glycaemic control. - Rifampin: may reduce sitagliptin exposure. - ACE inhibitors: monitor blood pressure and renal function during combined therapy.